## What is claimed is:

- 1. A method of producing complete Hepatitis A Virus particles comprising the steps of treating an HAV preparation from a cell culture supernatant of an HAV infected cell culture with a nucleic acid degrading agent and a protease, and isolating said purified preparation of complete HAV particles.
- 2. The method according to claim 1, which further comprises concentrating said cell culture supernatant prior to treating said nucleic acid degrading agent and protease.
- 3. The method according to claim 2, which comprises concentrating said cell culture supernatant by filtering.
- 4. The method of claim 1, wherein the nucleic acid degrading agent is an enzyme.
- 5. The method according to claim 4, wherein the enzyme is a DNase.
- 6. The method according to claim 1, wherein the protease is a microbial protease.
- 7. The method according to claim 1, wherein said protease is Pronase or an enzymatically active fraction thereof.
- 8. The method according to <u>claim</u> 1, wherein said protease is purified *Streptomyces griseus* trypsin.
- 9. A method according to claim 1, wherein the cell culture is a VERO cell culture.

- 10. The method according to claim 1, wherein said cells are grown in a serum free or serum and protein free medium.
- 11. The method according to claim 1, wherein said preparation of purified complete HAV particles is isolated by filtering.
- 12. The method according to claim 1, wherein said preparation of complete HAV particle has less than about 30 pg contaminating nucleic acid/ IU HAV antigen.
- 13. The method according to claim 1, wherein said preparation of complete HAV particle has at least about 5000 IU of HAV antigen / mg protein.
- 14. The method according to claim 1, further comprising a step of treating the preparation of complete HAV particle with a virus inactivating agent.
- 15. A method of production of a purified Hepatitis A Virus preparation comprising the steps of treating the HAV preparation from the supernatant of an HAV infected cell culture with a nucleic acid degrading agent and a protease, isolating said purified preparation of complete HAV particles and isolating purified mature HAV virions from said preparation complete HAV particle.
- 16. The method according to <u>claim</u> 15, which comprises concentrating said cell culture supernatant prior to treating said nucleic acid degrading agent and protease.
- 17. The method according to <u>claim</u> 16, which comprises concentrating said cell culture supernatant by filtering.

- 18. The method of claim 15, wherein the nucleic acid degrading agent is an enzyme.
- 19. The method according to claim 15, wherein the protease is a microbial protease.
- 20. A method according to claim 15, wherein the cell culture is a VERO cell culture.
- 21. The method according to claim 15, wherein said cells are grown in a serum free or serum and protein free medium.
- 22. The method according to claim 15, wherein said preparation is substantially free of contaminating proteins from the cells or the cell culture medium.
- 23. The method according to claim 15, wherein said preparation has less than about 0.5 pg contaminating nucleic acid /IU HAV antigen.
- 24. The method according to claim 15, comprising a step of treating the purified HAV particles with a virus inactivating agent.
- 25. The method according to claim 24, wherein treating of purified HAV particles with a virus inactivating agent is performed prior to isolation of mature HAV virions.
- 26. A method of production of a purified complete HAV particle preparation consisting which consists of purifying complete HAV particles from a cell culture supernatant an HAV infected cells by filtering.

- 27. The method according to claim 26, comprising further treating said preparation with a virus inactivating agent.
- 28. A method of production of a purified mature HAV particle preparation which consists of purifying mature HAV particles from a cell culture supernatant of HAV infected cells by filtering and centrifugation.
- 29. The method according to claim 28 which comprises further treating with a virus inactivating agent.
- 30. A method of isolating complete HAV particle from a cell-free cell culture supernatant of HAV infected cells comprising the steps of treating the HAV preparation from the supernatant of an HAV infected cell culture with a nucleic acid degrading agent and a protease, and isolating said purified preparation of complete HAV particles.
- 31. The method according to claim 30, wherein the preparation is free of HAV precursor polypeptide.
- 32. A method of isolating mature HAV particle from a cell culture supernatant HAV harvest of HAV infected cells comprising the steps of treating the HAV preparation from the supernatant of an HAV infected cell culture with a nucleic acid degrading agent and a protease, isolating said purified preparation of complete HAV, and isolating from said preparation of complete HAV particle a preparation consisting of mature HAV particle.
- 33. A preparation of complete HAV particle free of HAV precursor polypeptide and contaminating cell or cell culture protein.

- 34. The preparation according to claim 33, wherein said preparation has less than about 30 pg contaminating nucleic acid / IU HAV antigen.
- 35. The preparation according to claim 34, wherein said preparation has at least about 5000 IU of HAV antigen / mg protein.
- 36. The preparation according to claim 33, consisting of inactivated, purified complete HAV particles.
- 37. A preparation of purified mature HAV particle free of HAV precursor polypeptide and contaminating cell or cell culture protein.
- 38. The preparation according to claim 37, which is free of HAV provirions.
- 39. The preparation according to claim 37, wherein said preparation has less than about 0.5 pg contaminating nucleic acid from the cells or the cell culture / IU of HAV antigen.
- 40. The preparation according to claim 38, consisting of inactivated, purified mature HAV particles.
- 41. A method for production of HAV vaccine comprising the steps of treating an HAV preparation from the cell culture supernatant of an HAV infected cell culture with a nucleic acid degrading agent and a protease, and isolating said purified preparation of complete HAV particles, and preparing an immunogenic composition comprising a preparation consisting of purified, complete HAV virions.
- 42. A method for the production of an HAV vaccine comprising the steps of treating the HAV preparation from the supernatant of an HAV infected cell culture

with a nucleic acid degrading agent and a protease, isolating said purified preparation of complete HAV particles and isolating purified mature HAV virions from said preparation complete HAV particle, and preparing an immunogenic composition comprising a preparation consisting of purified, mature HAV virions.

- 43. The method according to claim 42, wherein the vaccine is substantially free of contaminating proteins from the cell culture.
- 44. A method for production of an inactivated HAV vaccine comprising the steps of treating the HAV preparation from the supernatant of an HAV infected cell culture with a nucleic acid degrading agent and a protease, isolating said purified preparation of complete HAV particles and isolating purified mature HAV virions from said preparation complete HAV particle, and preparing an immunogenic composition comprising a preparation, wherein the HAV preparation is treated with an inactivation agent prior or after isolating of mature HAV virion particle.
- 45. AN HAV vaccine comprising an host protective amount of a mature HAV particle preparation according to claim 37.
- 46. A vaccine according to claim 45, wherein said preparation is free of HAV precursor polypeptide and HAV provirions.
- 47. The vaccine according to claim 45, wherein said host protective dose is less than about 25 IU of HAV antigen / dose:
- 48. The vaccine according to claim 45, wherein said host protective dose is between about 10 and about 25 IU of HAV antigen / dose.

- 49. The vaccine according to claim 45, comprising an immune stimulating agent.
- 50. The vaccine according to claim 45, further comprising Hepatitis B virus antigen.
- 51. The vaccine according to claim 45, further comprising an antigen from a viral or bacterial pathogen.